CF PharmTech repurchases 24,000 H shares, spending HKD 0.53 million

Bulletin Express04-30 18:04

CF PharmTech, Inc. (02652.HK) bought back 24,000 H-shares on the Hong Kong Stock Exchange on 30 April 2026. The repurchase was executed at prices ranging from HKD 21.86 to HKD 22.26 per share, translating into a volume-weighted average cost of HKD 22.07 and a total consideration of HKD 0.53 million.

Following the transaction, issued shares (excluding treasury stock) decreased from 301.58 million to 301.56 million, while treasury shares rose from 641,000 to 665,000. The 24,000 shares repurchased represent 0.008 % of the company’s outstanding share capital at the opening balance on 28 April 2026. The total number of issued shares, including treasury shares, remained unchanged at 302.22 million.

The buyback forms part of a mandate granted on 16 December 2025, which authorises CF PharmTech to repurchase up to 30.22 million shares. Cumulative buybacks under this mandate now stand at 665,000 shares, equivalent to 0.22 % of the issued share base on the mandate date.

Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or disposal of treasury shares until 30 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199879514?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199879514","market":"us","top_or_hot":-1,"title":"CF PharmTech repurchases 24,000 H shares, spending HKD 0.53 million","media":"Bulletin Express","content":"<p>CF PharmTech, Inc. (02652.HK) bought back 24,000 H-shares on the Hong Kong Stock Exchange on 30 April 2026. The repurchase was executed at prices ranging from HKD 21.86 to HKD 22.26 per share, translating into a volume-weighted average cost of HKD 22.07 and a total consideration of HKD 0.53 million.</p>\n<p>Following the transaction, issued shares (excluding treasury stock) decreased from 301.58 million to 301.56 million, while treasury shares rose from 641,000 to 665,000. The 24,000 shares repurchased represent 0.008 % of the company’s outstanding share capital at the opening balance on 28 April 2026. The total number of issued shares, including treasury shares, remained unchanged at 302.22 million.</p>\n<p>The buyback forms part of a mandate granted on 16 December 2025, which authorises CF PharmTech to repurchase up to 30.22 million shares. Cumulative buybacks under this mandate now stand at 665,000 shares, equivalent to 0.22 % of the issued share base on the mandate date.</p>\n<p>Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or disposal of treasury shares until 30 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech repurchases 24,000 H shares, spending HKD 0.53 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech repurchases 24,000 H shares, spending HKD 0.53 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-30 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CF PharmTech, Inc. (02652.HK) bought back 24,000 H-shares on the Hong Kong Stock Exchange on 30 April 2026. The repurchase was executed at prices ranging from HKD 21.86 to HKD 22.26 per share, translating into a volume-weighted average cost of HKD 22.07 and a total consideration of HKD 0.53 million.</p>\n<p>Following the transaction, issued shares (excluding treasury stock) decreased from 301.58 million to 301.56 million, while treasury shares rose from 641,000 to 665,000. The 24,000 shares repurchased represent 0.008 % of the company’s outstanding share capital at the opening balance on 28 April 2026. The total number of issued shares, including treasury shares, remained unchanged at 302.22 million.</p>\n<p>The buyback forms part of a mandate granted on 16 December 2025, which authorises CF PharmTech to repurchase up to 30.22 million shares. Cumulative buybacks under this mandate now stand at 665,000 shares, equivalent to 0.22 % of the issued share base on the mandate date.</p>\n<p>Under Hong Kong listing rules, the company is subject to a moratorium on new share issues or disposal of treasury shares until 30 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"长风药业","start_time":0,"source_url":"","article_id":"1199879514","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199879514","pubTimestamp":1777543476,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CF PharmTech, Inc. (02652.HK) bought back 24,000 H-shares on the Hong Kong Stock Exchange on 30 April 2026. The repurchase was executed at prices ranging from HKD 21.86 to HKD 22.26 per share,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PharmTech回购2.4万股H股耗资53万港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PharmTech, Inc. (02652.HK) bought back 24,000 H-shares on the Hong Kong Stock Exchange on 30 April 2026. The repurchase was executed at prices ranging from HKD 21.86 to HKD 22.26 per share, translating into a volume-weighted average cost of HKD 22.07 and a total consideration of HKD 0.53 million.\nFollowing the transaction, issued shares (excluding treasury stock) decreased from 301.58 million to 301.56 million, while treasury shares rose from 641,000 to 665,000. The 24,000 shares repurchased represent 0.008 % of the company’s outstanding share capital at the opening balance on 28 April 2026. The total number of issued shares, including treasury shares, remained unchanged at 302.22 million.\nThe buyback forms part of a mandate granted on 16 December 2025, which authorises CF PharmTech to repurchase up to 30.22 million shares. Cumulative buybacks under this mandate now stand at 665,000 shares, equivalent to 0.22 % of the issued share base on the mandate date.\nUnder Hong Kong listing rules, the company is subject to a moratorium on new share issues or disposal of treasury shares until 30 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199879514","isCrawlerRequest":true}